BioSpace

FDA accuses Baxter leaders of ‘inadequate’ oversight after finding GMP failings

The recurrence of violations at multiple sites led the FDA to conclude that Baxter management must improve its oversight and control of manufacturing.

By BioSpace

1 min read
FDA accuses Baxter leaders of ‘inadequate’ oversight after finding GMP failings
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights